EUCTR2017-004323-72-ES进行中（未招募）1 期
Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancers with either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD) – The LUZERN Strategy – - LUZER
Medica Scientia Innovation Research (MedSIR)0 个研究点目标入组 23 人开始时间: 2019年12月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1.Male or female patients = 18 years of age. ECOG 0-1
- •2.Life expectancy =16 weeks.
- •3.Patients have radiologic evidence of inoperable locally recurrent or metastatic breast cancer (MBC) that are not candidates for curative intent.
- •4.Patients have (HER2)- negative and (HR)-positive breast cancer
- •5.[Cohort A]: Patients with documented germinal mutation in BRCA1 or BRCA2 genes Germinal BRCA assays carried out prior to enrollment will be accepted.
- •6.[Exploratory cohort B]: Patients with either germinal BRCA1/2 wild-type (gBRCAwt) or gBRCAms that are considered to be non- detrimental and homologous recombination deficiency (HRD) based on the HRDetect predictor test.
- •7.[Exploratory cohort B]: Willingness and ability to provide additional six formalin-fixed paraffin-embedded (FFPE) tissue slides from the most recent tumor tissue since last progression (from either metastasis or primary tumor) to centrally perform the RAD51 assay.
- •8.At least one and up to two prior lines of endocrine therapy (aromatase inhibitors [AIs] or fulvestrant) for treatment of locally recurrent and/or metastatic disease (except for patients progressing in the neoadjuvant or adjuvant setting).
- •9.Confirmed disease progression while in the last AI-containing regimen:
- •a.Progression on adjuvant AI-based regimen, confirmed after at least 2 years of ongoing therapy and within 12 months following adjuvant treatment interruption; OR,
- •b.Progression to at least one AI-based regimen for treatment of locally recurrent and/or metastatic disease after having achieved clinical benefit (at least 24 weeks on treatment). Confirmation of progression must be within 6 weeks after the end of treatment for locally recurrent and/or metastatic disease.
- •10.Patients may have progressed on no more than one chemotherapy regimens in the metastatic setting.
- •11.The following will not be counted as a prior line of cytotoxic chemotherapy:
- •a.Prior hormonal therapy and non-hormonal targeted therapy.
- •b.Targeted and biologic therapies.
- •12.The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as this was started at least 5 days prior to study treatment.
- •13.Prior carboplatin- or other platinum compound-based therapy is not allowed.
- •14.Patients must have evaluable or measurable disease according to (RECIST) criteria version 1.1. Patient with bone-only metastases are eligible.
- •15. Willingness and ability to provide the most recent tumor biopsy since last progression from either metastatic or primary tissues both at the time of the inclusion and at disease progression or study termination in order to perform exploratory studies.
- •16.Patients must agree to provide blood samples at the time of study inclusion, every three cycles of treatment, and upon disease progression or study termination in order to perform exploratory studies.
- •17.Adequate hematologic and organ function within 28 days before the first study treatment on Cycle 1 Day 1
- •18.Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to study treatment and must agree to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or patients of nonchildbearing potential.
- •19.Female patients must agree not to breastfeed during the study and for 180 days after the last dose of study treatment.
- •20.Male pati
排除标准
- •Exclusion Criteria:
- •1.HER2-positive disease based on local laboratory results (performed by IHC/in situhybridization test) or unknown HER2 status.
- •2.Patients that are candidates for a local treatment with a radical intention.
- •3.Patients that have previously received any PARP inhibitor (PARPi), including niraparib, in metastatic setting.
- •4.Patients must not be simultaneously enrolled in any interventional clinical trial and must not have received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
- •5.Patients who have had radiation therapy encompassing >20% of the bone marrow within 2 weeks prior to start of treatment, excepting for palliative radiation therapy to a small field >1 week prior to Day 1 of study.
- •6.Patients with visceral crisis who require chemotherapy.
- •7.Patients must not have a known hypersensitivity to niraparib components or excipients.
- •8.Patients must not have received a transfusion (platelets or red blood cells) = 4 weeks prior to initiating protocol therapy.
- •9.Patients must not have received colony-stimulating factors within 4 weeks prior initiating protocol therapy.
- •10.Patients have had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy in adjuvant setting or cyclin-dependent kinases (CDK)4/6inhibitors that persisted > 4 weeks and was related to the most recent treatment.
- •11.Patients must not have any known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).
- •12.Patients with symptomatic uncontrolled brain metastases or leptomeningealmetastases.
- •13.Patients must not have had diagnosis, detection, or treatment of another type of cancer = 2 years prior to initiating protocol therapy
- •14.Patients with symptomatic uncontrolled brain metastases or leptomeningeal metastases.
- •15.Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
- •16.Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- •17.Chronic daily treatment with corticosteroids with a dose of = 10 mg/day methylprednisolone equivalent (excluding inhaled steroids), except for prophylaxis use.
- •18.Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute myeloid leukemiaewly diagnosed secondary or high risk AMLMedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2018-004353-24-ESFundación PETHEMA59
招募中
2 期
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients
GMMG-CONCEPTMultiple Myeloma2024-511791-32-00University Medical Center Hamburg-Eppendorf246
已完成
不适用
An open-label, multi-center, 2-arm PhaseI/II trial of LBY135 alone and in combination with capecitabine in advanced solid tumorsAdvanced solid tumors and Colorectal Cancer10027476NL-OMON29725ovartis25
进行中（未招募）
1 期
MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.Human Immunodeficiency Virus-1 infectionMedDRA version: 20.1 Level: PT Classification code 10000807 Term: Acute HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2015-003616-20-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60
进行中（未招募）
1 期
MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.Human Immunodeficiency Virus-1 infectionEUCTR2015-003616-20-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.60